Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure-Reference-Cited by-同舟云学术

Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure

Published:2024-05-15 Issue:9 Volume:65 Page:1378-1380
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Despas Fabien¹^ORCID,Chaouki Maria²³,de Barros Sandra¹,Bonneau Baptiste¹,Allal Ben²³⁴,Guillermet-Guibert Julie²³,Ysebaert Loïc²³⁵

Affiliation:

1. Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d‘Informations sur le Médicament, CIC INSERM 1436, Faculté de Médecine, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

2. Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Institut National de la Santé et de la Recherche Médicale (Inserm) U1037, Centre National de la Recherche Scientifique (CNRS) U5071, Toulouse, France

3. TouCAN (Laboratoire d‘Excellence Toulouse Cancer), Toulouse, France

4. Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopôle, Centre Hospitalier Universitare de Toulouse, Toulouse, France

5. Service d‘Hématologie, Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2353330

Reference14 articles.

1. PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

2. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

3. Management of adverse events associated with idelalisib treatment: expert panel opinion

4. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma

5. FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in combination with other cancer medicines. US Food & Drug Administration; 2016. Accessed April 24 2024. https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-healthcare-professionals-about-clinical-trials-zydelig-idelalisib-combination-other